UUD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe absence of material debt lowers financial risk and avoids significant interest or refinancing burdens. This gives Syntara more balance-sheet flexibility than in earlier leveraged periods, although the benefit is defensive because profitability and cash generation remain weak.
Substantial Equity CushionA sizable equity base relative to assets provides a stronger capital cushion and may help absorb continuing losses over the medium term. This reduces immediate balance-sheet vulnerability and gives the company more capacity to manage operations while pursuing improvement.
Demonstrated Historical Gross ProfitabilityThe historical gross margin indicates that Syntara previously generated positive economics after direct costs when it had meaningful revenue. If revenue returns, this evidence supports potential operating leverage, though current results do not yet demonstrate that profitability has been restored.
Bears Say
Persistent And Worsening Net LossesContinuing net and operating losses weaken internal capital formation and make the business dependent on its existing resources or future funding. The larger FY2026 net loss suggests that profitability has not stabilized, limiting the company’s ability to compound value from operations.
No Meaningful Recent RevenueThe absence of recorded revenue leaves Syntara without a demonstrated current revenue engine to support its cost base. This makes earnings highly loss-driven, reduces visibility into commercial scale, and weakens confidence that operations can become self-funding over the next several months.
Sustained Operating And Free Cash BurnLarge recurring cash outflows consume the company’s resources even though the balance sheet carries little debt. Continued operating and free cash burn can force reliance on funding or available liquidity, reducing financial flexibility and increasing the importance of reversing losses.
Syntara Limited News
UUD FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Currently, no data Available
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is CHF27.31M.
When is Pharmaxis Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaxis Ltd’s earnings last quarter?
Currently, no data Available
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Currently, no data Available
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in CH:UUD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syntara Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF0.06 (― Upside)
CHF0.06 (― Upside)
Blogger Sentiment
Bullish
CH:UUD Sentiment 86%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharmaxis Ltd
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
UUD Stock 12 Month Forecast
Average Price Target
―Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―